• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性心肌梗死患者静脉输注重组人组织型纤溶酶原激活剂期间的凝血与纤溶分析

Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.

作者信息

Collen D, Bounameaux H, De Cock F, Lijnen H R, Verstraete M

出版信息

Circulation. 1986 Mar;73(3):511-7. doi: 10.1161/01.cir.73.3.511.

DOI:10.1161/01.cir.73.3.511
PMID:2419009
Abstract

Coagulation and fibrinolysis were studied in patients with acute myocardial infarction during intravenous infusion of recombinant human tissue-type plasminogen activator (rt-PA) (0.75 mg/kg over 90 min, n = 101), streptokinase (1,500,000 IU over 60 min, n = 61), or placebo (n = 40). In the rt-PA group, the plasma level of rt-PA antigen was 1.2 +/- 0.6 micrograms/ml (mean +/- SD) and the euglobulin fibrinolytic activity (EFA) was 910 +/- 735 IU t-PA/ml. In the streptokinase group, the EFA was equivalent to 430 +/- 435 IU t-PA/ml. At the end of the infusion, the plasma fibrinogen level measured with a coagulation rate assay was decreased to 57 +/- 33% of the preinfusion value in the rt-PA group, to 7 +/- 10% in the streptokinase group, and remained unchanged in the placebo group. Fibrinogen-fibrin degradation products increased to 0.75 +/- 0.54 mg/ml in the streptokinase group but to only 0.10 +/- 0.13 mg/ml in the rt-PA group. The plasma levels of alpha 2-antiplasmin, plasminogen, and factor V decreased to between 30% and 45% in the rt-PA group but significantly more in the streptokinase group (to between 15% and 25%). Thus rt-PA induced much less systemic fibrinolytic activation than streptokinase. In the patients who received rt-PA, a weak correlation (r = .21, n = 89, .1 greater than p greater than .05) was found between the extent of fibrinogen breakdown at 90 min and the plasma rt-PA concentration.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在急性心肌梗死患者静脉输注重组人组织型纤溶酶原激活剂(rt-PA)(90分钟内输注0.75mg/kg,n = 101)、链激酶(60分钟内输注1,500,000IU,n = 61)或安慰剂(n = 40)期间,对凝血和纤溶进行了研究。在rt-PA组中,rt-PA抗原的血浆水平为1.2±0.6μg/ml(均值±标准差),优球蛋白纤溶活性(EFA)为910±735IU t-PA/ml。在链激酶组中,EFA相当于430±435IU t-PA/ml。输注结束时,用凝血速率测定法测得的血浆纤维蛋白原水平在rt-PA组降至输注前值的57±33%,在链激酶组降至7±10%,而在安慰剂组保持不变。纤维蛋白原-纤维蛋白降解产物在链激酶组增加至0.75±0.54mg/ml,但在rt-PA组仅增加至0.10±0.13mg/ml。rt-PA组中α2-抗纤溶酶、纤溶酶原和因子V的血浆水平降至30%至45%之间,但在链激酶组中下降幅度更大(降至15%至25%之间)。因此,rt-PA诱导的全身纤溶激活比链激酶少得多。在接受rt-PA的患者中,发现90分钟时纤维蛋白原分解程度与血浆rt-PA浓度之间存在弱相关性(r = 0.21,n = 89,0.1>p>0.05)。

相似文献

1
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.急性心肌梗死患者静脉输注重组人组织型纤溶酶原激活剂期间的凝血与纤溶分析
Circulation. 1986 Mar;73(3):511-7. doi: 10.1161/01.cir.73.3.511.
2
Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.心肌梗死溶栓治疗(TIMI)试验——I期:接受重组组织型纤溶酶原激活剂和链激酶治疗患者的出血表现以及血浆纤维蛋白原和纤溶系统的变化
J Am Coll Cardiol. 1988 Jan;11(1):1-11. doi: 10.1016/0735-1097(88)90158-1.
3
[Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].静脉注射重组组织型纤溶酶原激活剂与静脉注射链激酶治疗急性心肌梗死患者有效性的比较随机研究。欧洲重组组织型纤溶酶原激活剂合作研究组报告
Klin Wochenschr. 1988;66 Suppl 12:77-85.
4
Thrombolytic versus fibrinogenolytic activity of rt-PA and streptokinase in patients with acute myocardial infarction.急性心肌梗死患者中rt-PA和链激酶的溶栓与纤维蛋白溶解活性
Angiology. 1990 Aug;41(8):616-20. doi: 10.1177/000331979004100805.
5
Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.
Lancet. 1985 Apr 13;1(8433):842-7. doi: 10.1016/s0140-6736(85)92208-1.
6
New developments in thrombolytic therapy.溶栓治疗的新进展。
Adv Exp Med Biol. 1990;281:333-54.
7
Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction.
J Am Coll Cardiol. 1989 Jan;13(1):19-26. doi: 10.1016/0735-1097(89)90543-3.
8
Alterations in the fibrinolytic system components during acute myocardial infarction.急性心肌梗死期间纤溶系统成分的改变。
Acta Cardiol. 2000 Aug;55(4):247-53. doi: 10.2143/AC.55.4.2005747.
9
Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.采用重组组织型纤溶酶原激活剂(rt-PA)和重组单链尿激酶型纤溶酶原激活剂(rscu-PA)低剂量协同组合进行冠状动脉溶栓治疗急性心肌梗死。
Am J Cardiol. 1987 Sep 1;60(7):431-4. doi: 10.1016/0002-9149(87)90280-3.
10
Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction.
Ann Intern Med. 1991 Mar 1;114(5):417-23. doi: 10.7326/0003-4819-114-5-417.

引用本文的文献

1
Post-thrombolytic coagulopathy and complications in patients with pulmonary embolism treated with fixed-dose systemic alteplase.溶栓后凝血功能障碍与固定剂量全身性阿替普酶治疗肺栓塞患者的并发症。
J Thromb Thrombolysis. 2022 Nov;54(4):605-615. doi: 10.1007/s11239-022-02640-6. Epub 2022 Mar 23.
2
Mathematical Modelling of Intravenous Thrombolysis in Acute Ischaemic stroke: Effects of Dose Regimens on Levels of Fibrinolytic Proteins and Clot Lysis Time.急性缺血性卒中静脉溶栓的数学建模:剂量方案对纤溶蛋白水平和血栓溶解时间的影响
Pharmaceutics. 2019 Mar 7;11(3):111. doi: 10.3390/pharmaceutics11030111.
3
Computational Simulations of Thrombolytic Therapy in Acute Ischaemic Stroke.
急性缺血性脑卒中溶栓治疗的计算模拟。
Sci Rep. 2018 Oct 25;8(1):15810. doi: 10.1038/s41598-018-34082-7.
4
Early changes in fibrinogen after administration of alteplase are associated with the short-term efficacy of thrombolysis.使用阿替普酶后纤维蛋白原的早期变化与溶栓的短期疗效相关。
Medicine (Baltimore). 2018 Mar;97(13):e0241. doi: 10.1097/MD.0000000000010241.
5
Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard?急性缺血性脑卒中的小剂量静脉注射组织型纤溶酶原激活物:替代治疗还是新标准?
Stroke Vasc Neurol. 2016 Oct 25;1(3):115-121. doi: 10.1136/svn-2016-000033. eCollection 2016 Sep.
6
α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.α2-抗纤溶酶:缺血性中风的新见解与机遇
Semin Thromb Hemost. 2017 Mar;43(2):191-199. doi: 10.1055/s-0036-1585077. Epub 2016 Jul 29.
7
Endovascular treatment for acute ischemic stroke patients: implications and interpretation of IMS III, MR RESCUE, and SYNTHESIS EXPANSION trials: A report from the Working Group of International Congress of Interventional Neurology.急性缺血性卒中患者的血管内治疗:IMS III、MR RESCUE及SYNTHESIS EXPANSION试验的意义与解读:国际介入神经病学大会工作组报告
J Vasc Interv Neurol. 2014 May;7(1):56-75.
8
Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model.洛伐他汀短期大剂量给药对人全血体外血栓模型中 rt-PA 溶栓的影响。
Curr Neurovasc Res. 2012 Aug;9(3):207-13. doi: 10.2174/156720212801619054.
9
Tissue-type plasminogen activator as a therapeutic target in stroke.组织型纤溶酶原激活剂作为中风的治疗靶点。
Expert Opin Ther Targets. 2008 Feb;12(2):159-70. doi: 10.1517/14728222.12.2.159.
10
Current state of thrombolytic therapy.
Curr Cardiol Rep. 1999 Sep;1(3):212-20. doi: 10.1007/s11886-999-0025-9.